Moleculin BiotechMBRX
MBRX
About: Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Employees: 17
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
11% more funds holding
Funds holding: 18 [Q3] → 20 (+2) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
1.59% less ownership
Funds ownership: 16.16% [Q3] → 14.57% (-1.59%) [Q4]
40% less capital invested
Capital invested by funds: $1.31M [Q3] → $790K (-$518K) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
360%
upside
Avg. target
$6
591%
upside
High target
$8
821%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Jason McCarthy 14% 1-year accuracy 5 / 35 met price target | 360%upside $4 | Buy Upgraded | 25 Mar 2025 |
HC Wainwright & Co. Vernon Bernardino 12% 1-year accuracy 8 / 66 met price target | 821%upside $8 | Buy Reiterated | 25 Mar 2025 |
Financial journalist opinion
Based on 9 articles about MBRX published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
Moleculin Biotech (MBRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
3 days ago
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also known as “Ara-C” and for which the combination of Annamycin and Ara-C is referred to as “AnnAraC”) for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML). This Phase 3 “MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) is a global approval trial, including sites in the US, Europe and the Middle East.
Positive
Zacks Investment Research
1 week ago
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Seeking Alpha
1 week ago
Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO John Paul Waymack - Senior CMO Jonathan Foster - EVP and CFO Conference Call Participants Jonathan Aschoff - Roth Capital Partners Jason McCarthy - Maxim Group Vernon Bernardino - H.C. Wainwright Operator Hello, and welcome to the Moleculin Biotech Fourth Quarter and Full Year 2024 Update Conference Call and Webcast.
Neutral
GlobeNewsWire
1 week ago
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in the first quarter of 2025
Neutral
GlobeNewsWire
2 weeks ago
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Monday morning, March 24, 2025 at 8:30 AM ET.
Neutral
PRNewsWire
3 weeks ago
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
On-demand video webcast now available here HOUSTON , March 11, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company") a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it participated in the Virtual Investor "Top 5 for '25" On-Demand Conference. As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Moleculin in 2025.
Neutral
PRNewsWire
3 weeks ago
Moleculin to Present at the 37th Annual ROTH Conference
Live webcast fireside chat on Tuesday, March 18 th at 11:00 AM PT HOUSTON , March 10, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Walter Klemp, Chairman and Chief Executive Officer of Moleculin will participate in a fireside chat on Tuesday, March 18, 2025 at 11:00 AM PT at the 37th Annual ROTH Conference being held in Dana Point, CA. In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.
Neutral
PRNewsWire
4 weeks ago
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity
New patents will extend coverage to major markets outside the U.S., expanding upon existing U.S. claims Affirms expectations for an initial data readout of the phase 3 MIRACLE trial for the second half of 2025 HOUSTON , March 6, 2025 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received a Notice of Intent to Grant for the European patent application titled, "Method of Reconstituting Liposomal Annamycin". The grant is subject to payment of fees and completion of final amendments and formalities.
Neutral
PRNewsWire
1 month ago
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
HOUSTON , March 3, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its abstract has been accepted for poster presentation at the Acute Leukemias XIX (ISALXIX) International Symposium being held March 16-19, 2025 in Munich, Germany. Details for the poster presentation are as follows: Abstract: P002 Session: Clinical Studies in AML and ALL Title: Liposomal Annamycin in Combination with Cytarabine for Treatment of Acute Myeloid Leukemia (AML) Presenting Author: Cristina Papayannidis, MD, PhD, Adjunct professor, Department of Medical and Surgical Sciences, University of Bologna, Bologna Italy For more information about the ISALXIX International Symposium, visit the event website.
Charts implemented using Lightweight Charts™